Navigation Links
Stereotaxis Highlights Live Coronary and Peripheral Vascular Cases Performed at TCT With Stereotaxis Magnetic Navigation System
Date:10/25/2007

here can be no assurance that we will recognize revenue related to our purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of our control. In addition, these orders and commitments may be revised, modified or canceled, either by their express terms, as a result of negotiations, or by project changes or delays.


'/>"/>
SOURCE Stereotaxis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Chennai AIDS Campaign Highlights The Social Neglect Faced By Victims
2. Benzene Slick In China Highlights Water Pollution
3. Homecare Association Highlights Cost-Effectiveness of Medicare and Medicaid
4. Study Highlights Appetite Regulation Pathway, New Hope for Weight Loss
5. Study Highlights How Bacteria Respond To Changes In Environment
6. Highlights from World Transplant Congress
7. Latest IPCC Report Highlights Need for Integrated Climate/human Behavior Models
8. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development
9. New York Legislature Highlights for Awareness of Alzheimers Disease
10. New Critical Path Report Highlights Research Needed to Foster Generic Drug Development
11. EU Drug Regulator Highlights Depression Danger of Weight-loss Pill
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 2ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 3ThromboGenics Announces Start of Phase II Trial of Microplasmin for the Treatment of Age-Related Macular Degeneration (AMD) 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 2Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 3Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 4Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 5Phase III CONFIRM Study Shows FASLODEX(R) (fulvestrant) Injection 500 mg May Delay Time of Disease Progression Over 250-mg Dose in Postmenopausal Women With Hormone Receptor-Positive Advanced Breast Cancer 6Lack of happiness hormone serotonin in the brain causes impaired maternal behavior in mice 8972 1Energy saving method checks refrigerant level in air conditioners 8970 1Energy saving method checks refrigerant level in air conditioners 8970 2How to text message and avoid pain 8968 1How to text message and avoid pain 8968 2